Eduardo Pagani
Valinhos, SP, Brazil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
A phase I, open-label study of intravenous human dental pulp stem cells (NestaCell®) at two dose levels in patients with Huntington's disease.
Journal: Stem cell research & therapy
Published: April 03, 2025
Phase II trial of intravenous human dental pulp stem cell therapy for Huntington's disease: a randomized, double-blind, placebo-controlled study.
Journal: Stem cell research & therapy
Published: March 31, 2025
Technology Readiness Level Roadmap for Developing Innovative Herbal Medicinal Products.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: April 19, 2024
Advanced cell therapy with low tissue factor loaded product NestaCell® does not confer thrombogenic risk for critically ill COVID-19 heparin-treated patients.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: March 01, 2022
Human Immature Dental Pulp Stem Cells Did Not Graft into a Preexisting Human Lung Adenocarcinoma.
Journal: Case reports in oncology
Published: January 31, 2022
Why are biosimilars much more complex than generics?
Journal: Einstein (Sao Paulo, Brazil)
Published: February 28, 2019
Acetaminophen absorption and metabolism in an intestine/liver microphysiological system.
Journal: Chemico-biological interactions
Published: February 15, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026